Clinical TrialJul 8, 2026, 09:46 AM
MAIA Biotech THIO-101 Phase 2 Part C shows 90.5% DCR in NSCLC
AI Summary
MAIA Biotechnology announced positive initial efficacy data from Part C of its Phase 2 THIO-101 clinical trial for advanced non-small cell lung cancer (NSCLC). The combination therapy of ateganosine and cemiplimab achieved a 90.5% disease control rate (DCR) in a heavily pre-treated patient population, significantly higher than the 25-35% DCR seen with current chemotherapy treatments. This data aligns with previous positive results from Parts A and B of the trial, and an acceptable safety profile has been observed to date.
Key Highlights
- THIO-101 Phase 2 Part C showed 90.5% disease control rate (DCR).
- 19 out of 21 efficacy-evaluable patients achieved disease control.
- Standard-of-care chemotherapy typically delivers 25-35% DCR.
- Patients in Part C were heavily pre-treated, including docetaxel.
- Previous Parts A and B of THIO-101 showed an 88% DCR.
- Ateganosine followed by cemiplimab demonstrated an acceptable safety profile.
Price Impact
More from MAIA